Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Rockledge, Pennsylvania Clinical Trials

A listing of Rockledge, Pennsylvania clinical trials actively recruiting patient volunteers.

RESULTS

Found (1082) clinical trials

A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant

The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe and effective in the treatment of relapsed and refractory Classical Hodgkin Lymphoma. The participants of this trial will comprise of patients who have relapsed or did ...

Phase

1.35 miles

Learn More »

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

OBJECTIVES Primary Phase II Determine the feasibility of conducting a cooperative group prospective clinical trial in patients with resected malignant salivary gland tumors. Acquire preliminary efficacy data comparing postoperative radiotherapy alone to concurrent chemotherapy and radiation using weekly cisplatin. Phase III Compare overall survival rates among patients receiving cisplatin and ...

Phase

1.35 miles

Learn More »

Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients

1 Cycle = 28 days = 4 weeks. Treatment will be administered on an outpatient basis Metformin starting dose is 500 mg BID, will be gradually increased to target dose of 1000mg BID. Treatment ARM A Cycles 1 - 2: Observation without treatment Cycles 3 - 8: Bicalutamide 50 mg ...

Phase

1.35 miles

Learn More »

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

PRIMARY OBJECTIVES: I. To determine the progression free survival (PFS) at 3 months and response rate defined as complete response (CR) and partial response (PR) in angiosarcoma patients treated with pazopanib. SECONDARY OBJECTIVES: I. To assess overall survival of patients treated with pazopanib. II. To gather more safety data for ...

Phase

1.35 miles

Learn More »

A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma

This phase 1 study will determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of ONC201, when given as a single agent, to patients with advanced solid tumors or multiple myeloma, in two dose schedules including every 3 weeks and weekly. For the first arm (A), dose ...

Phase

1.35 miles

Learn More »

S1613 Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

PRIMARY OBJECTIVES: I. To evaluate the efficacy of trastuzumab and pertuzumab (TP) (Arm 1) in HER-2 amplified metastatic colorectal cancer (mCRC) by comparing progression-free survival (PFS) on TP compared to control arm (Arm 2) of cetuximab and irinotecan hydrochloride (irinotecan) (CETIRI). SECONDARY OBJECTIVES: I. To evaluate the overall response rate ...

Phase

1.35 miles

Learn More »

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

This is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with imatinib and 1 or 2 other TKIs.

Phase

1.35 miles

Learn More »

Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

PRIMARY OBJECTIVES: I. To determine disease free survival (DFS) and overall survival (OS) in all patients with muscle-invasive bladder and upper-tract urothelial carcinoma treated with adjuvant pembrolizumab (MK-3475) versus (vs.) observation. SECONDARY OBJECTIVES: I. To determine DFS and OS in PD-L1 positive and negative patients with muscle-invasive bladder and upper-tract ...

Phase

1.35 miles

Learn More »

Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy

Primary Objective The primary objective of this proposal is to evaluate gemcitabine as a method of MDSC depletion. Secondary Objectives Evaluate whether these measures result in enhanced T-cell activity and/or NK cell function and number. Determine the tolerability and clinical activity (including response rate and survival) of this approach. Correlate ...

Phase

1.35 miles

Learn More »

Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

PRIMARY OBJECTIVES: I. To compare invasive disease-free survival (IDFS) of patients with triple-negative breast cancer (TNBC) who have either >= 1 cm residual invasive breast cancer and/or positive lymph nodes (> ypN+) after neoadjuvant chemotherapy randomized to receive 1 year of MK-3475 (pembrolizumab) adjuvant therapy compared to no MK-3475 (pembrolizumab), ...

Phase

1.35 miles

Learn More »